Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ventus Therapeutics, Inc.

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Provides Updates on cGAS Inhibitor Program at Keystone Symposium on Innate Immunity
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Chief Scientific Officer Michael Crackower, Ph.D., to Present on ReSOLVE™ Platform at Next Generation Undruggable Conference
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Opens New Facility in Waltham, MA as First Phase of Global Expansion
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Promotes Daniel Koerwer to Chief Operating Officer
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Awarded Grant by the U.S. Department of Defense to Study the Role of cGAS in Lupus
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Appoints Stuart Green, M.D., as Chief Medical Officer
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Appoints Victor Lobanov, PhD, as Head of Computational Sciences
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Appoints Christine Ha as Chief Financial Officer
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Closes $140 Million Series C Financing
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics to Present Data for Novel Peripherally Restricted and Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases
From Ventus Therapeutics, Inc.
Via Business Wire
Ventus Therapeutics Closes $100 Million Series B Financing
From Ventus Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.